{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:13:00Z","timestamp":1760026380092,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ajem.2015.02.049","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T11:57:36Z","timestamp":1425643056000},"page":"1329.e5-1329.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epistaxis complicated by rivaroxaban managed with topical tranexamic acid"],"prefix":"10.1016","volume":"33","author":[{"given":"Mark D.","family":"Utkewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia I.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2015.02.049_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000276741","article-title":"Effect of local tranexamic acid gel in the treatment of epistaxis","volume":"57","author":"Tibbelin","year":"1995","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"10.1016\/j.ajem.2015.02.049_bb0010","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ajem.2013.06.043","article-title":"A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial","volume":"31","author":"Zahed","year":"2013","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2015.02.049_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0005-2795(75)90216-0","article-title":"Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids","volume":"393","author":"Thorsen","year":"1975","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ajem.2015.02.049_bb0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0304-4165(81)90312-3","article-title":"Studies on the mechanism of the antifibrinolytic action of tranexamic acid","volume":"673","author":"Hoylaerts","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ajem.2015.02.049_bb0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajem.2015.02.049_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ajem.2015.02.049_bb0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.905.905","article-title":"The effect of extreme age and gender on the pharmacology and tolerability of rivaroxaban, an oral direct Xa inhibitor","volume":"108","author":"Kubitza","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ajem.2015.02.049_bb0040","first-page":"293476","article-title":"Bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion","volume":"2014","author":"Gruenebaum","year":"2014","journal-title":"Case Rep Cardiol"},{"year":"2015","series-title":"Xarelto [package insert]","key":"10.1016\/j.ajem.2015.02.049_bb0045"},{"key":"10.1016\/j.ajem.2015.02.049_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: a review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.ajem.2015.02.049_bb0055","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajem.2015.02.049_bb0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1538-7836.2010.04098.x","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays","volume":"9","author":"Hillarp","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ajem.2015.02.049_bb0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1160\/TH10-10-0667","article-title":"Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time","volume":"106","author":"Mani","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajem.2015.02.049_bb0070","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.12173","article-title":"Normal prothrombin time in the presence of therapeutic levels of rivaroxaban","volume":"160","author":"van Veen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ajem.2015.02.049_bb0075","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ajem.2015.02.049_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jemermed.2012.11.032","article-title":"Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians","volume":"45","author":"Brem","year":"2013","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ajem.2015.02.049_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/2319-4170.125627","article-title":"Thromboprophylaxis after minimally invasive total knee arthroplasty: a comparison of rivaroxaban and enoxaparin","volume":"37","author":"Yen","year":"2014","journal-title":"Biomed J"},{"key":"10.1016\/j.ajem.2015.02.049_bb0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.otsr.2011.12.005","article-title":"Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients","volume":"98","author":"Clav\u00e9","year":"2012","journal-title":"Orthop Traumatol Surg Res"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675715001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675715001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:29:07Z","timestamp":1760023747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675715001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0735675715001394"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2015.02.049","relation":{},"ISSN":["0735-6757"],"issn-type":[{"type":"print","value":"0735-6757"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epistaxis complicated by rivaroxaban managed with topical tranexamic acid","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2015.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}